JP2021523114A5 - - Google Patents
Info
- Publication number
- JP2021523114A5 JP2021523114A5 JP2020561635A JP2020561635A JP2021523114A5 JP 2021523114 A5 JP2021523114 A5 JP 2021523114A5 JP 2020561635 A JP2020561635 A JP 2020561635A JP 2020561635 A JP2020561635 A JP 2020561635A JP 2021523114 A5 JP2021523114 A5 JP 2021523114A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- celduratinib
- cocrystal
- solvate
- pharmaceutically acceptable
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024001279A JP2024024093A (ja) | 2018-05-04 | 2024-01-09 | リンパ腫の治療方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667249P | 2018-05-04 | 2018-05-04 | |
| US62/667,249 | 2018-05-04 | ||
| US201862678934P | 2018-05-31 | 2018-05-31 | |
| US62/678,934 | 2018-05-31 | ||
| US201862736047P | 2018-09-25 | 2018-09-25 | |
| US62/736,047 | 2018-09-25 | ||
| PCT/US2019/030690 WO2019213589A1 (en) | 2018-05-04 | 2019-05-03 | Methods for treating lymphoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001279A Division JP2024024093A (ja) | 2018-05-04 | 2024-01-09 | リンパ腫の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523114A JP2021523114A (ja) | 2021-09-02 |
| JPWO2019213589A5 JPWO2019213589A5 (https=) | 2022-05-18 |
| JP2021523114A5 true JP2021523114A5 (https=) | 2022-05-18 |
Family
ID=66554509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561635A Pending JP2021523114A (ja) | 2018-05-04 | 2019-05-03 | リンパ腫の治療方法 |
| JP2024001279A Pending JP2024024093A (ja) | 2018-05-04 | 2024-01-09 | リンパ腫の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001279A Pending JP2024024093A (ja) | 2018-05-04 | 2024-01-09 | リンパ腫の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11266645B2 (https=) |
| EP (1) | EP3787628A1 (https=) |
| JP (2) | JP2021523114A (https=) |
| KR (1) | KR20210003789A (https=) |
| CN (1) | CN112074271B (https=) |
| AU (1) | AU2019262644A1 (https=) |
| BR (1) | BR112020022430A2 (https=) |
| CA (1) | CA3098012A1 (https=) |
| MX (1) | MX2020011817A (https=) |
| TW (1) | TW202014190A (https=) |
| WO (1) | WO2019213589A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3788035B1 (en) | 2018-05-04 | 2024-08-07 | Alexion Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| US10851087B2 (en) | 2018-05-04 | 2020-12-01 | Portola Pharmaceuticals, Inc. | Synthesis of cerdulatinib |
| WO2023091785A1 (en) * | 2021-11-22 | 2023-05-25 | Secura Bio, Inc. | Methods for treating peripheral t-cell lymphoma |
| CN114306606B (zh) * | 2021-11-29 | 2023-05-26 | 江苏省人民医院（南京医科大学第一附属医院） | cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用 |
| CN115177620A (zh) * | 2022-07-18 | 2022-10-14 | 厦门大学附属第一医院 | 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用 |
| WO2024115935A1 (en) * | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
| CN117427166B (zh) * | 2023-09-25 | 2024-09-10 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Csf1r抑制剂用于制备nk/t细胞淋巴瘤治疗药物的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2340091C (en) * | 1998-08-11 | 2013-02-05 | Idec Pharmaceuticals Corporation | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| EP1845778A2 (en) | 2005-01-10 | 2007-10-24 | University Of Virginia Patent Foundation | Synthesis of inhibitors of p90rsk |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| WO2016196385A1 (en) * | 2015-05-29 | 2016-12-08 | Portola Pharmaceuticals, Inc. | Cerdulatinib for the treatment of b-cell malignancies |
| AU2016363005A1 (en) * | 2015-12-04 | 2018-07-05 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating hematological cancers |
-
2019
- 2019-05-03 EP EP19724683.8A patent/EP3787628A1/en not_active Withdrawn
- 2019-05-03 TW TW108115469A patent/TW202014190A/zh unknown
- 2019-05-03 MX MX2020011817A patent/MX2020011817A/es unknown
- 2019-05-03 CN CN201980029463.1A patent/CN112074271B/zh active Active
- 2019-05-03 WO PCT/US2019/030690 patent/WO2019213589A1/en not_active Ceased
- 2019-05-03 CA CA3098012A patent/CA3098012A1/en active Pending
- 2019-05-03 AU AU2019262644A patent/AU2019262644A1/en not_active Abandoned
- 2019-05-03 KR KR1020207032288A patent/KR20210003789A/ko not_active Withdrawn
- 2019-05-03 BR BR112020022430-8A patent/BR112020022430A2/pt not_active Application Discontinuation
- 2019-05-03 JP JP2020561635A patent/JP2021523114A/ja active Pending
- 2019-05-03 US US16/403,227 patent/US11266645B2/en active Active
-
2022
- 2022-01-31 US US17/589,562 patent/US20220233533A1/en not_active Abandoned
-
2024
- 2024-01-09 JP JP2024001279A patent/JP2024024093A/ja active Pending
-
2025
- 2025-02-01 US US19/043,427 patent/US20250213562A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523114A5 (https=) | ||
| EP4110338A1 (en) | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor | |
| Fenelon et al. | Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study | |
| RU2015120616A (ru) | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы | |
| US20040029869A1 (en) | Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine | |
| US8492383B2 (en) | Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia | |
| EP3010505A1 (en) | Pharmaceutical combinations | |
| JP2018520117A5 (https=) | ||
| JP2018535996A5 (https=) | ||
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| PT2177223E (pt) | Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, envolvendo a homoharringtonina isoladamente ou em combinação com outros agentes | |
| WO2022090443A1 (en) | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor | |
| HUE028025T2 (en) | Use of Panobinostat HDAC inhibitor to treat myeloma | |
| JPWO2019213589A5 (https=) | ||
| IL292882A (en) | Dosage of Bruton's tyrosine kinase inhibitor | |
| EP3664787B1 (en) | Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors | |
| JP2006508118A5 (https=) | ||
| JP2024517788A (ja) | Ｍｐｎｓｔの処置のための化合物及び組成物 | |
| Freerksen et al. | Malaria therapy and prophylaxis with cotrifazid, a multiple complex combination consisting of rifampicin+ isoniazid+ sulfamethoxazole+ trimethoprim | |
| Florea et al. | Focus on... Voriconazole A novel azole antifungal. | |
| EP3130339B1 (en) | A compound for use in the treatment of comorbid anxiety disorder and depression disorder | |
| CN101282728A (zh) | 有机化合物的组合 | |
| Bronson et al. | Το Market, Το Market-2012 | |
| WO1995020388A1 (en) | Anti-hiv drugs | |
| NZ788615B2 (en) | Dosing of a bruton's tyrosine kinase inhibitor |